戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  binge intake of high-fat food (HFF) seen in binge eating disorder.
2 jor eating disorders and a related syndrome, Binge Eating Disorder.
3 se female patients meeting full criteria for binge eating disorder.
4 ppressant d-fenfluramine in the treatment of binge eating disorder.
5 requency of binge eating by obese women with binge eating disorder.
6 rgery patients-in particular, depression and binge eating disorder.
7 stigation towards pharmacologically treating binge eating disorder.
8 trial to test the efficacy of sibutramine in binge eating disorder.
9 e in risk is specific for the development of binge eating disorder.
10 al abuse and discrimination) in the risk for binge eating disorder.
11 ctive and well tolerated in the treatment of binge eating disorder.
12 e efficacy of sertraline in the treatment of binge eating disorder.
13 t outcome measures in the acute treatment of binge-eating disorder.
14  efficacy of fluvoxamine in the treatment of binge-eating disorder.
15 ffective, especially for bulimia nervosa and binge-eating disorder.
16 for bulimia nervosa and lisdexamfetamine for binge-eating disorder.
17 f efficacy in adults with moderate to severe binge-eating disorder.
18 and topiramate reduced weight in adults with binge-eating disorder.
19 he characteristic symptomatology observed in binge-eating disorder.
20 as a potential pharmacological treatment for binge-eating disorder.
21 ic substrate for observed sex differences in binge-eating disorder.
22 o time did any participant meet criteria for binge-eating disorder.
23 ns of anorexia nervosa, bulimia nervosa, and binge-eating disorder.
24 ns of anorexia nervosa, bulimia nervosa, and binge-eating disorder.
25 derstanding of the etiology and treatment of binge eating disorders.
26  remains no direct evidence for this link in binge-eating disorders.
27 exia nervosa, 0.12%; bulimia nervosa, 0.08%; binge eating disorder, 0.42%).
28  were depression (19% [95% CI, 14%-25%]) and binge eating disorder (17% [95% CI, 13%-21%]).
29   Among a referred sample of 207 adults with binge-eating disorder, 187 participants (160 females [85
30                         Lisdexamfetamine for binge eating disorder (4 RCTs; n = 900) was associated w
31 in 3.7% of patients (79 of 2123), comprising binge-eating disorder (53 of 79 [67.1%]), anorexia nervo
32 balanced factorial design, 136 patients with binge-eating disorder (81.6% women; mean age, 46.5 years
33 ies reporting pharmacological treatments for binge eating disorder, advances in treatment for adults
34                                              Binge-eating disorder aggregated strongly in families in
35 N=4, 0.4%) met criteria for bulimia nervosa; binge eating disorder also was more common among white w
36 f 300 overweight or obese probands (150 with binge eating disorder and 150 with no lifetime eating di
37         A community sample of 162 women with binge eating disorder and 251 healthy and 107 psychiatri
38 sorimotor putamen was altered in humans with binge eating disorder and bulimia nervosa and that the d
39 d bulimia nervosa and more likely to exhibit binge eating disorder and eating disorder not otherwise
40 ating and obesity, emphasizing binge eating, binge eating disorder and food addiction as useful conce
41 5 and 5 y of follow-up, 134 individuals with binge-eating disorder and 134 individuals with no histor
42 o assess longitudinally the relation between binge-eating disorder and components of the metabolic sy
43 ries are: anorexia nervosa, bulimia nervosa, binge eating disorder, and eating disorder not otherwise
44 ession (76.3% for bulimia nervosa, 65.5% for binge-eating disorder, and 49.5% for anorexia nervosa) a
45 9.0%) with bulimia nervosa, 757 (11.4%) with binge-eating disorder, and 589 (8.9%) with avoidant/rest
46 s include anorexia nervosa, bulimia nervosa, binge-eating disorder, and avoidant/restrictive food int
47 ther eating disorders (OED: bulimia nervosa, binge-eating disorder, and eating disorder not otherwise
48                 This study assesses obesity, binge eating disorder, anorexia nervosa, and bulimia ner
49               The best treatment options for binge-eating disorder are unclear.
50 rders (anorexia nervosa, bulimia nervosa and binge-eating disorder) are a heterogeneous class of comp
51 sa and bulimia nervosa; and the inclusion of binge eating disorder as a formal diagnosis.
52 y of research also supports the inclusion of binge eating disorder as a formal diagnosis.
53 port for conceptualizing bulimia nervosa and binge eating disorder as discrete syndromes.
54 s to evaluate topiramate in the treatment of binge eating disorder associated with obesity.
55 ell tolerated in the short-term treatment of binge eating disorder associated with obesity.
56  systems: anorexia nervosa, bulimia nervosa, binge eating disorder, avoidant-restrictive food intake
57 prevalence of eating disorders (EDs) such as binge eating disorder (BED) and bulimia nervosa (BN) amo
58 nomenological and diagnostic overlap between binge eating disorder (BED) and substance use disorders
59               While bulimia nervosa (BN) and binge eating disorder (BED) are prevalent in military po
60                     Bulimia nervosa (BN) and binge eating disorder (BED) are the most prevalent eatin
61                                              Binge eating disorder (BED) is a public health concern t
62                                              Binge eating disorder (BED) is characterized by regular
63                                              Binge eating disorder (BED) is one of the most frequent
64                                              Binge eating disorder (BED) is the most common eating di
65 ticipants were veterans who met criteria for Binge Eating Disorder (BED) or subthreshold BED, had a b
66 l survey, the average lifetime prevalence of binge eating disorder (BED) was 2%.
67 dexamfetamine dimesylate (LDX) vs placebo in binge eating disorder (BED) was evaluated in two multice
68 teen obese individuals seeking treatment for binge eating disorder (BED) were compared with 19 non-BE
69  subjects with (n = 30) and without (n = 30) binge eating disorder (BED) were compared with matched h
70 anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), and purging disorder (PD).
71 ents the criterion standard for treatment of binge eating disorder (BED), most individuals do not hav
72 anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), other specified feeding and
73 tunity for intervention in patients with the binge eating disorder (BED).
74 n phenotypes: pathological gambling (PG) and binge eating disorder (BED).
75 ide the United States on the epidemiology of binge eating disorder (BED).
76 IPT) is an effective specialty treatment for binge eating disorder (BED).
77 has documented efficacy for the treatment of binge eating disorder (BED).
78 exia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED)].
79                                              Binge-eating disorder (BED) is a prevalent, costly publi
80                                              Binge-eating disorder (BED) is characterized by recurrin
81                                              Binge-eating disorder (BED), a public health problem ass
82 l or food, in alcohol use disorders (AUD) or binge-eating disorder (BED), suggest a disturbance in ex
83                                              Binge-eating disorder (BED)-a syndrome that only recentl
84                                   Women with binge-eating disorder (BED; n = 38) and age- and weight-
85                                   Women with binge-eating disorder before and during pregnancy had hi
86 a before and during pregnancy and those with binge-eating disorder before pregnancy exhibit dietary p
87                        Eating disorders (eg, binge eating disorder, bulimia nervosa, and anorexia ner
88 sorder and 2.9% had partial or full-criteria binge eating disorder but no association with the outcom
89 tom severity among referred populations with binge eating disorder, but pharmacotherapies were also a
90 ding eating disorders such as overeating and binge-eating disorder, but the brain structural mechanis
91 or attention deficit hyperactivity disorder, binge eating disorder, cocaine addiction, obesity, and t
92 ade for atypical eating disorders except for binge-eating disorder (cognitive behavioural therapy was
93  loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity.
94 t lisdexamfetamine reduce binge frequency in binge-eating disorder compared with placebo (antidepress
95 trol disorders, including gambling disorder, binge eating disorder, compulsive sexual behaviour, and
96                 Eligible adults met DSM-IV-R binge-eating disorder criteria and had moderate to sever
97 up intakes of women with bulimia nervosa and binge-eating disorder during pregnancy and compared thes
98                          Women with incident binge-eating disorder during pregnancy had higher intake
99         Two RCTs (n = 465) of topiramate for binge eating disorder found larger reductions in YBOCS-B
100 disorder criteria and had moderate to severe binge eating disorder (>/=3 binge-eating days per week f
101  with anorexia nervosa, bulimia nervosa, and binge-eating disorder have high lifetime rates of depres
102 sibutramine is effective in the treatment of binge eating disorder, impacting both binge eating and w
103                         Guided self-help for binge eating disorder improved eating disorder symptom s
104  proof of concept phase II clinical trial in binge eating disorder in 2022.
105         This study assessed the stability of binge eating disorder in a community sample.
106 ce of anorexia nervosa, bulimia nervosa, and binge eating disorder in a geographically and economical
107 s for anorexia nervosa, bulimia nervosa, and binge eating disorder in adult women are 1.42%, 0.46%, a
108 ciated with an increased risk for developing binge eating disorder in black women and in white women
109   Our findings support a distinct subtype of binge eating disorder in obesity with similarities in ri
110 comparison of individuals with and without a binge-eating disorder in analyses adjusted for age, sex,
111 ncts to psychotherapy for bulimia nervosa or binge-eating disorder; in the case of anorexia nervosa,
112                             The Internet and Binge Eating Disorder (INTERBED) study is a prospective,
113                                              Binge eating disorder is an addiction-like disorder char
114                                              Binge eating disorder is associated with obesity.
115                  These findings suggest that binge eating disorder is at least as chronic as the well
116                                              Binge-eating disorder is a familial disorder caused in p
117                                              Binge-eating disorder is a newly described eating disord
118                                              Binge-eating disorder is characterized by excessive, unc
119 binge-eating behavior.SIGNIFICANCE STATEMENT Binge-eating disorder is the most common eating disorder
120                                              Binge-eating disorder is the most common eating disorder
121 led group cognitive-behavioral treatment for binge eating disorder led to higher binge eating abstine
122                                              Binge-eating disorder may confer a risk of components of
123                                              Binge-eating disorder may represent a risk factor for th
124 s among relatives with lifetime diagnoses of binge eating disorder (N=131), bulimia nervosa (N=17), a
125 rvosa (n = 13), bulimia nervosa (n = 6), and binge-eating disorder (n = 1), published between January
126 5% CI, -0.17 to -0.03 percentage points) and binge-eating disorder of low frequency and/or limited du
127 tive relevance of loss-of-control eating and binge-eating disorder of low frequency and/or limited du
128 dy mass index >=18.5, met criteria for DSM-5 binge eating disorder or bulimia nervosa, had 12 months
129 gnosis of anorexia nervosa, bulimia nervosa, binge eating disorder, or eating disorder not otherwise
130 chological stress impairs self-regulation in binge-eating disorders, or that any such self-regulatory
131 n circuits and neurotransmitters involved in binge-eating disorder pathology and identify RXFP3 as a
132 on across the genome of anorexia nervosa and binge-eating disorder patients.
133                          In black women with binge eating disorder, rates of sexual abuse, physical a
134                                              Binge-eating disorder remains underrecognized and infreq
135                          White subjects with binge eating disorder reported significantly higher rate
136                                              Binge eating disorder represents a public health problem
137 ical conditions, including ADHD, depression, binge eating disorder, schizophrenia, Alzheimer disease,
138 n the anticipation of rewards, subjects with binge eating disorder show greater risk-taking, similar
139 ere significantly higher in white women with binge eating disorder than in matched psychiatric compar
140 ere significantly higher in black women with binge eating disorder than in psychiatric comparison sub
141 pled with a lack of control over eating, and binge eating disorder, the Diagnostic and Statistical Ma
142                                              Binge-eating disorder, the most prevalent eating disorde
143  was to compare three types of treatment for binge eating disorder to determine the relative efficacy
144                The mean lifetime duration of binge eating disorder was 14.4 years (SD=13.9), signific
145                       Neither depression nor binge eating disorder was consistently associated with d
146 ity randomized clinical trial of adults with binge-eating disorder was conducted between November 202
147         A total of 259 adults diagnosed with binge eating disorder were randomly assigned to 20 weeks
148 icipants (N=304) who met DSM-IV criteria for binge eating disorder were randomly assigned to 24 weeks
149          Thirty-four outpatients with DSM-IV binge eating disorder were randomly assigned to receive
150                         Anorexia nervosa and binge eating disorder were relatively uncommon.
151 es of anorexia nervosa, bulimia nervosa, and binge-eating disorder were 0.3%, 0.9%, and 1.6%, respect
152 -five outpatients with a DSM-IV diagnosis of binge-eating disorder were randomly assigned to receive
153 l, 61 outpatients (53 women, eight men) with binge eating disorder who were obese (body mass index >/
154 tablished treatments for bulimia nervosa and binge eating disorder, with stepped-care approaches show
155  associated with significant improvements in binge-eating disorder, with a consistent pattern of BWL
156  duration, may be an effective treatment for binge-eating disorder, yet it is rarely offered or only

 
Page Top